Perinatal Precision Medicine (NSIGHT2)

• ClinicalTrials.gov Identifier: NCT03211039
• Recruitment Status: Active, not recruiting
• First Posted: July 7, 2017
• Results First Posted: February 27, 2023
• Last Update Posted: February 27, 2023
• Sponsor: Rady Pediatric Genomics & Systems Medicine Institute
• Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Human Genome Research Institute (NHGRI)
• Information provided by (Responsible Party): Stephen F. Kingsmore, Rady Pediatric Genomics & Systems Medicine Institute

Study Description

Brief Summary:

This study will seek to determine if rapid genomic sequencing improves outcomes for acutely ill infants. The investigator will enroll up to 1,000 acutely ill infants in a prospective, randomized, blinded study to either rapid Whole Genome Sequencing (WGS) or rapid Whole Exome Sequencing (WES, which is 2% of the genome and ~4-fold less expensive). 213 infants were actually enrolled. Outcomes will be measured both by objective clinical measures and family perceptions (patient/family centered outcomes). Primary analysis of WGS or WES will be in infants alone. Secondary analysis, in infants who do not receive a diagnosis, will be of families - ideally trios (mother, father, and affected infant), which is ~2-fold more expensive. Trios will be analyzed within the same randomization arm (WGS or WES). This study is designed to quantify which acutely ill infants benefit from rapid genomic sequencing, by how much they benefit, how they benefit, which rapid genomic sequencing method is superior, and the cost effectiveness of such testing.

Condition or disease	Intervention/treatment	Phase
Genetic Diseases; Genetic Syndrome; Mendelian Disorders	Genetic: Genomic sequencing and molecular diagnostic results, if any.	Not Applicable

Detailed Description:

Acutely ill infant inpatients who have an undiagnosed illness, and their families, will be eligible to participate in the study. The investigators will enroll up to 1,000 infants. Locally, the study population will be recruited from Rady Children's Hospital (RCH) inpatient population, primarily the neonatal intensive care unit (NICU), pediatric intensive care unit (PICU), and cardiovascular intensive care unit (CVICU), with a smaller population presenting to other hospital in-patient services. Recruitment will be targeted at the RCH main campus, but it may include referrals from satellite locations in the RCH network (particularly the RCH NICU network throughout San Diego County). All patients will continue to receive routine care as clinically indicated, including the state newborn screen and other genetic testing as determined by their treating providers. Half of the affected study participants will be randomized to receive rapid whole genome sequencing (WGS) and the other half will receive rapid whole exome sequencing (WES). Each arm will initially be analyzed using the patient's (proband's) sample only. If a proband-only analysis fails to yield a diagnosis, genomic data from the biological family members (typically parents), when available, will be used to supplement analysis (trio analysis). Occasionally, a second affected sibling may be available for family analysis. Not infrequently, the father is not available for study. Similarly, the investigators anticipate the need for targeted genetic analysis of biological parents, and possibly other family members, to confirm diagnostic results and/or provide additional information regarding inheritance.

The investigators anticipate that in rare cases a newborn may be so ill that the team lacks equipoise that the child can wait for the estimated ten day turnaround time of our send-out exome testing. In these rare cases, the PI, or his delegate, will decide if the child is not eligible for randomization. These children will remain in the research study throughout the entirety of the study, but will receive in-house ultra-rapid whole genome sequencing by the Rady Children's Institute for Genomic Medicine (RCIGM, also called RadyPGSMI) laboratory in lieu of either a rapid genome or rapid exome (both anticipated to be 10 day turn-arounds).

Enrollment will be sought within the first 96 hours following admission to RCH or an RCH network ICU or within 96 hours of meeting criteria for the study if the infant was not previously eligible. Patients and their family members who consent to participate will have their blood drawn and will be randomized to receive either rapid WGS or rapid WES. The initial symptom-driven analysis will be conducted on the patient's sample only (singleton analysis). If a diagnosis is not found promptly (within 24 hours) via a singleton analysis, the family (or any combination of parents and/or other family members) will be analyzed using the same technology that the patient was randomized to receive. Pathogenic and likely pathogenic variants (as determined by American College of Medical Genetics (ACMG) guidelines) that relate in part or in whole to the patient's current phenotype will be clinically confirmed and reported into the patients' medical record. Although the intention of the study is to return symptom-driven results to the medical record, the clinical report for confirmation of symptom-driven findings may include negative findings of testing. In the event that our analysis incidentally finds a pathogenic variant for which a treatment or intervention exists to improve morbidity and/or mortality, families may choose not to receive this additional information.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 213 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

The initial symptom-driven analysis will be conducted on the patient's (NICU infants) sample only (singleton analysis). Patients will be randomized to receive either whole genome sequencing or whole exome sequencing. If a diagnosis is not found promptly (within 24 hours) via singleton analysis, sequential analysis of the family (or any combination of parents and/or other family members) will be analyzed using the same technology that the patient was randomized to receive.

The study includes parental and physician questionnaires to understand perceptions regarding testing. There is no randomization of parents or physicians nor a requirement to respond to the questionnaires for the patient (NICU infant) to participate in the study.

Enrollment: 213 patients (NICU infants)

• Masking: Single (Participant)
• Masking Description: Patients (NICU infants) and their parents, the patient's providers, and the enrollment staff will be blinded to the randomization arm they receive.
• Primary Purpose: Diagnostic
• Official Title: Prenatal Precision Medicine (NSIGHT2): A Randomized, Blinded, Prospective Study of the Clinical Utility of Rapid Genomic Sequencing for Infants in the Acute-care Setting
• Actual Study Start Date: June 29, 2017
• Actual Primary Completion Date: October 9, 2018
• Estimated Study Completion Date: July 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Whole Genome Sequencing; Genetic test that looks at all coding and non-coding areas of the genome	Genetic: Genomic sequencing and molecular diagnostic results, if any.; Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
Whole Exome Sequencing; Genetic test that looks at all coding areas of the genome	Genetic: Genomic sequencing and molecular diagnostic results, if any.; Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.

Outcome Measures

Primary Outcome Measures :

1. Subject's Main Provider's Perceived Clinical Utility of Genomic Sequencing [ Time Frame: Within one week of the return of results ]
   Perceived utility/benefit of sequencing based on "Clinician Assessment" questionnaire completed by patient's providers. Question: Was the test clinically useful? Response was measured on a 5-point Likert scale (very useful=5, useful=4, neutral=3, not very useful=2, not useful at all=1.
2. Test Results Led to Change in Patient Management [ Time Frame: Within 1 week of return of results ]

   Test results led to Change in clinical management (select all that apply):

   • Surgical intervention added
   • Surgical intervention removed
   • Surgical intervention changed
   • Medication added
   • Medication removed
   • Medication changed
   • Diet changed
   • New specialty service sought
   • Prior specialty service no longer required
   • New imaging sought
   • Prior imaging cancelled
   • New test ordered
   • Prior testing cancelled
   • Screening for additional comorbidities added
   • Screening for additional comorbidities removed
   • Palliative care initiated
   • Palliative care withdrawn
   • Other: (text box for written description)
3. Test Led to Changes in Management That Altered Patient Outcome [ Time Frame: 1 year ]
   Primary physician perception of change in outcome

Secondary Outcome Measures :

1. Diagnostic Proportion for Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) [ Time Frame: Within approximately 30 days of enrollment ]
   WGS and WES are two clinical diagnostic test modalities. Results of testing were placed in the electronic medical record. Results either provided a molecular diagnosis that explained the patient's condition or did not. The diagnostic proportion is the number of patients who received a molecular diagnosis by the test modality divided by the total number of patients who were tested by that modality.
2. Result Within 7 Days of Sample Receipt [ Time Frame: Within 7 days of sample receipt ]
   Time to result.
3. Parental Perceived Usefulness of Test [ Time Frame: Within one week of the return of results and approximately one year after enrollment ]
   Parental perception that test was useful
4. Parental Perception of Test Benefit for Their Infant [ Time Frame: Within one week of the return of results and approximately one year after enrollment ]
   Parental perception that the test benefitted their infant
5. Parental Decisional Regret With Sequencing [ Time Frame: Within one week of the return of results and approximately one year after enrollment ]
   Markers of harm in genetic diagnosis as evidenced by Brehaut's Decisional Regret scale. Scale 0-100. Higher scores indicate higher regret.

Eligibility Criteria

• Ages Eligible for Study: up to 4 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Individual in whom one of the following criteria is met:

1. Acutely ill inpatient of less than 4 months of age and within 96 hours of admission.
2. Acutely ill inpatient of less than 4 months of age and within 96 hours of development of an abnormal response to standard therapy for an underlying condition.
3. Acutely ill inpatient of less than 4 months of age and within 96 hours of development of clinical feature or laboratory test value suggestive of a genetic condition.
4. Biological relative of an infant enrolled in this study.

Exclusion Criteria:

Inpatients of greater than 4 months of age, or who do not meet any of the inclusion criteria, or with:

1. Neonatal infection or sepsis with normal response to therapy
2. Isolated prematurity
3. Isolated unconjugated hyperbilirubinemia
4. Hypoxic Ischemic Encephalopathy with clear precipitating event
5. Previously confirmed genetic diagnosis that explains their clinical condition (i.e. have a positive genetic test)
6. Isolated Transient Neonatal Tachypnea
7. Permission is unable to be obtained by a legal guardian or court-appointed representative within 96 hours of becoming eligible for enrollment.
8. Non-viable neonates - newborns less than 28 days of life with a modified code status (only full code patients may be enrolled).

Contacts and Locations

Locations

United States, California

Rady Children's Institute for Genomic Medicine (RCIGM)

San Diego, California, United States, 92123

Sponsors and Collaborators

Rady Pediatric Genomics & Systems Medicine Institute

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Human Genome Research Institute (NHGRI)

Investigators

• Principal Investigator: Stephen F Kingsmore, MD, DSc; Rady Pediatric Genomics & Systems Medicine Institute

  Study Documents (Full-Text)

Documents provided by Stephen F. Kingsmore, Rady Pediatric Genomics & Systems Medicine Institute:

Study Protocol and Statistical Analysis Plan  [PDF] January 29, 2019

More Information

Publications of Results:

Dimmock DP, Clark MM, Gaughran M, Cakici JA, Caylor SA, Clarke C, Feddock M, Chowdhury S, Salz L, Cheung C, Bird LM, Hobbs C, Wigby K, Farnaes L, Bloss CS, Kingsmore SF; RCIGM Investigators. An RCT of Rapid Genomic Sequencing among Seriously Ill Infants Results in High Clinical Utility, Changes in Management, and Low Perceived Harm. Am J Hum Genet. 2020 Nov 5;107(5):942-952. doi: 10.1016/j.ajhg.2020.10.003.

Cakici JA, Dimmock DP, Caylor SA, Gaughran M, Clarke C, Triplett C, Clark MM, Kingsmore SF, Bloss CS. A Prospective Study of Parental Perceptions of Rapid Whole-Genome and -Exome Sequencing among Seriously Ill Infants. Am J Hum Genet. 2020 Nov 5;107(5):953-962. doi: 10.1016/j.ajhg.2020.10.004.

Kingsmore SF, Cakici JA, Clark MM, Gaughran M, Feddock M, Batalov S, Bainbridge MN, Carroll J, Caylor SA, Clarke C, Ding Y, Ellsworth K, Farnaes L, Hildreth A, Hobbs C, James K, Kint CI, Lenberg J, Nahas S, Prince L, Reyes I, Salz L, Sanford E, Schols P, Sweeney N, Tokita M, Veeraraghavan N, Watkins K, Wigby K, Wong T, Chowdhury S, Wright MS, Dimmock D; RCIGM Investigators. A Randomized, Controlled Trial of the Analytic and Diagnostic Performance of Singleton and Trio, Rapid Genome and Exome Sequencing in Ill Infants. Am J Hum Genet. 2019 Oct 3;105(4):719-733. doi: 10.1016/j.ajhg.2019.08.009. Epub 2019 Sep 26.

Other Publications:

Milko LV, Chen F, Chan K, Brower AM, Agrawal PB, Beggs AH, Berg JS, Brenner SE, Holm IA, Koenig BA, Parad RB, Powell CM, Kingsmore SF. FDA oversight of NSIGHT genomic research: the need for an integrated systems approach to regulation. NPJ Genom Med. 2019 Dec 10;4:32. doi: 10.1038/s41525-019-0105-8. eCollection 2019.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Laurenzano SE, McFall C, Nguyen L, Savla D, Coufal NG, Wright MS, Tokita M, Dimmock D, Kingsmore SF, Newfield RS. Neonatal diabetes mellitus due to a novel variant in the INS gene. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4):a004085. doi: 10.1101/mcs.a004085. Print 2019 Aug.

• Responsible Party: Stephen F. Kingsmore, President and CEO, Rady Pediatric Genomics & Systems Medicine Institute
• ClinicalTrials.gov Identifier: NCT03211039
• Other Study ID Numbers: 161983; U19HD077693 ( U.S. NIH Grant/Contract )
• First Posted: July 7, 2017
• Results First Posted: February 27, 2023
• Last Update Posted: February 27, 2023
• Last Verified: January 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Samples and data may be shared confidentially with collaborators, such as commercial laboratories or technology companies. All data and sample sharing will be strictly confidential. No identifying information will be shared.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF)
• Time Frame: Following publication of results; Indefinitely
• Access Criteria: Researchers must register at NBSTRN and request access to this dataset via the LPDR.
• URL: https://nbstrn.org/

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Stephen F. Kingsmore, Rady Pediatric Genomics & Systems Medicine Institute:

Neonate; Genomic Medicine; Rapid Precision Medicine; Rapid Whole Genome Sequencing; Diagnosis; Infant; Intensive care unit; clinical trial; Rapid Whole Exome Sequencing; Single locus disease; Ultra-rapid whole genome sequencing; Clinical Utility

Additional relevant MeSH terms:

Genetic Diseases, Inborn